Infectious Disease Clinical Development Expertise
Getting a novel infectious disease vaccine or treatment on the market today is extremely critical and complex.
Infectious diseases are a threat to global health and way of life everywhere – particularly in the midst of the current COVID-19 pandemic. Time is of the essence when it comes to developing safe and effective infectious disease vaccines and treatments. In addition to recent pandemic outbreaks caused by viral infections, more treatment-resistant bacterial and fungal infections are rising, with antibiotics and anti-fungals becoming less effective.
Our scientific-minded infectious disease experts can help navigate this challenging landscape, having conducted more than 300 projects for Infectious Disease treatments and vaccines.
Experience Battling Infectious Diseases
Whether you are aiming to prevent or combat a viral, bacterial, fungal or parasitic infection, Veristat can help make the difference for your study’s success. Our teams understand the nuances and difficulties involved with treating infectious diseases, have the experience to perform vaccine trials, and are adept with rapid response to global pandemics that arise, such as the current COVID-19 outbreakresponse.
At Veristat, our experienced teams are poised to plan and implement these efforts quickly providing:
- Development of regulatory strategy, expedited pathways, and regulatory agency interactions
- Clinical program planning, inclusive of statistical planning and analysis
- Agile patient recruitment strategies to support virtual trial and hybrid approaches
- Rapid deployment of clinical trial databases
- Virtual and remote clinical and medical site monitoring
- Data analysis and migration into CDISC formats
- Writing of clinical trial, safety, and regulatory documents
- Preparation and defense of Marketing Applications – NDAs, BLAs, NDSs, MAAs, jNDAs, etc.
Projects for infectious disease treatments and vaccines
vaccine projects for 2014 outbreak
Explore Our Recent Infectious Disease Experience
Prevention and Treatment of Bacterial & Fungal Infections
|Acinetobacter Baumannii Infections||Gram-Negative Infections|
|Acute Bacterial Skin and Skin Structure Infections (ABSSI)||H. Pylori Infection|
|Bacterial Pneumonia||Joint infection|
|Botulinum vaccine||Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia|
|Clostridium Difficile (C.Diff)||Nontuberculous Mycobacterial (NTM) Lung Disease|
|Complicated Intra-Abdominal Infections (cIAI)||Nosocomial Infection|
|Complicated Skin and Skin Structure Infection (CSSSI)||Onychomycosis|
|Complicated Urinary Tract Infection including Pyelonephritis||Staphylococcus Aureus|
|Cystic Fibrosis-Pseudomonas||Surgical Site Infections|
|Endocarditis||Vacomycin-Resistant Enterococcal Infections|
Prevention and Treatment of Viruses/Viral Infection
|COVID 19||Influenza - Pandemic|
|Cytomegalovirus (CMV) Infection||Lassa Fever|
|Epstein Barr Virus (EBV)||Middle East Respiratory Syndrome Coronavirus (MERS-CoV)|
|Hepatitis A, B & C||Recurrent Respiratory Papillomatosis (RRP)|
|Herpes (HSV2)||Respiratory Syncytial Virus|
|HIV / AIDS||RNA Vaccine Platforms for multiple types of Infectious Diseases/Cancers|
|Human Papilloma Virus (HPV)||Shingles - Varicella-Zoster Virus (VZV)|
|Influenza - H1N1||Smallpox|
|Influenza - H5N1||Sexually Transmitted Infections|
|Influenza - Seasonal||Typhoid Fever|
|Influenza (Universal Vaccine)||West Nile Virus|